<DOC>
	<DOCNO>NCT01652014</DOCNO>
	<brief_summary>This study determine safety applicability experimental form umbilical cord blood ( UCB ) transplantation patient high risk hematologic malignancy might benefit hematopoietic stem cell transplant ( HSCT ) standard donor option ( available HLA-matched related donor ( MRD ) , HLA-matched unrelated donor ( MUD ) ) , single UCB unit adequate cell number HLA-match ) .</brief_summary>
	<brief_title>Single Double Donor Umbilical Cord Blood Transplant Treating Patients With High-Risk Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients histologically proven hematologic malignancy anticipate 2 year survival &lt; 20 % standard therapy ; patient age &lt; 18 excluded virtue policy procedures allogeneic hematopoietic stem cell transplant ( HSCT ) program ( Cancer Institute New Jersey [ CINJ ] /Robert Wood Johnson University Hospital [ RWJUH ] approve Pediatric Transplant Center ) ; patient &gt; age 65 generally consider candidate experimental unrelated allogeneic HSCT , utilized study virtue anticipate delay immune reconstitution , high risk GVHD , know negative impact age outcomes Patients eligible trial high risk disease include , limited : Acute myeloid leukemia ( AML ) second complete remission ( CR2 ) great early relapse &lt; 5 % marrow blast circulate blast AML first complete remission ( CR1 ) high risk cytogenetics ( complex , monosomy 5 , monosomy 7 , 11q23 ( ( 9 ; 11 ) ) , ( 6 ; 9 ) , chromosome 3 , monosomy phenotype karyotype estimate = &lt; 20 % disease free survival 3 year ) secondary/transformed AML without favorable cytogenetics ; Acute lymphoblastic leukemia ( ALL ) ( 9 ; 22 ) , 11q23 abnormality early relapse ( &lt; 5 % marrow blast ) CR2 great ; Chronic myeloid leukemia ( CML ) resistant/refractory commercially available Abelson ( abl ) kinase inhibitor ( e.g . imatinib mesylate , dasatinib , nilotinib ) predict base upon clinical course abl kinase domain mutation analysis ; accelerate phase blast crisis ; High intermediate high international prognostic score myelodysplasia ; NonHodgkin lymphoma ( NHL ) /Hodgkin lymphoma ( HL ) /other lymphoproliferative disease resistant/refractory standard therapy autologous transplant consider inappropriate ( e.g . bone marrow involvement , chemotherapy refractory disease , prior transplant ) ; Chronic lymphocytic leukemia ( CLL ) resistant/refractory standard therapy ( e.g . fludarabine ) high risk cytogenetics/fluorescence situ hybridization ( FISH ) ( e.g . 17p ) ; Myeloproliferative disorder progressive disease cytopenias clinical symptom refractory standard therapy ( e.g . hypomethylating agent ) Relapsed refractory multiple myeloma ( eligible ) high dose chemotherapy/autologous hematopoietic stem cell rescue follow salvage therapy thalidomide , lenalidomide bortezomib/other Food Drug Administration ( FDA ) approve multiple myeloma salvage therapy ; Other hematologic malignancies/disorders anticipate 2 year survival &lt; 20 % , establish available data base , medical literature document consensus Hematologic Malignancies Tumor Study Group Patients must allogeneic HSCT candidate standard donor ( match relate donor [ MRD ] , human leukocyte antigen [ HLA ] match unrelated donor [ MUD ] single UCB unit appropriate size HLA type ) available Patients must available UCB unit ( ) Patients consider Arm 2 must eligible Arm 1 must HLAhaploidentical sibling , parent , child , relative ( uncle , aunt , first cousin , niece nephew ) meet donor requirement outline Donor Eligibility criteria Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Left ventricular ( LV ) ejection fraction &gt; = 50 % Diffusion capacity carbon monoxide ( DLCO ) correct hemoglobin &gt; 60 % Total bilirubin within normal institutional limit unless patient Gilbert 's disease Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) = &lt; 2.5 X institutional upper limit normal ( ULN ) Measured estimate creatinine clearance &gt; 50 ml/min Hematopoietic stem cell comorbidity index = &lt; 2 There must negative pregnancy test woman childbearing potential within 1 week therapy ; must willingness avoid pregnancy undergo counsel contraceptive technique throughout course treatment There must uncontrolled infection active acute chronic illness diabetes , angina/myocardial ischemia , cardiac arrhythmia , venous thrombosis/embolism , cerebrovascular disease , seizure disorder , psychiatric illness intercurrent illness well control anticipate difficult control propose therapy The patient must aware high risk experimental nature treatment provide inform consent The patient must clearance HSCT psychosocial evaluation The patient must adequate insurance support meet anticipated financial burden impose cost therapy DONOR ( allogeneic lymphocyte , Arm 2 ) : Relative ( parent , child , sibling , first cousin , uncle aunt , nephew , niece ) appropriate HLA match ( &gt; = 3/6 HLA A , B , DR match ) DONOR ( allogeneic lymphocyte , Arm 2 ) : Age &gt; = 18 year old DONOR ( allogeneic lymphocyte , Arm 2 ) : Normal hemogram ; potential donor normal hemogram may utilize discretion Principal Investigator DONOR ( allogeneic lymphocyte , Arm 2 ) : Not pregnant lactate DONOR ( allogeneic lymphocyte , Arm 2 ) : Not human immunodeficiency virus ( HIV ) 1 , HIV2 , hepatitis C ( HCV ) , Hepatitis B core human Tlymphotropic virus ( HTLV ) I/II seropositive ; hepatitis B surface antigen ( HB Sag ) ( ) ; must meet infectious disease screen criterion utilized New Brunswick Affiliated Hospital ( NBAH ) Blood Center DONOR ( allogeneic lymphocyte , Arm 2 ) : No uncontrolled infection , medical psychological/social condition , require medication might increase likelihood patient donor adverse effect poor outcome DONOR ( allogeneic lymphocyte , Arm 2 ) : Meet blood bank criterion blood product donation ( determine NBAH Blood Center screen history ) DONOR ( allogeneic lymphocyte , Arm 2 ) : Donors must inform investigational nature study , understand requirement , potential benefit potential risk experimental treatment , give write informed consent accordance institutional federal guideline Prior extensive radiation therapy radiation oncologist feel preclude additional TBI Patients know human immunodeficiency virus ( HIV ) exclude due side effect therapy immune system Patients know active central nervous system ( CNS ) disease exclude clinical trial often develop progressive neurologic dysfunction unresponsive HSCT therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>